Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, May 7th, RTT News reports. Shareholders of record on Thursday, May 17th will be paid a dividend of 0.5625 per share on Friday, June 8th. This represents a $2.25 annualized dividend and a yield of 2.86%.
Eli Lilly and has raised its dividend payment by an average of 2.0% per year over the last three years and has increased its dividend annually for the last 3 consecutive years. Eli Lilly and has a payout ratio of 53.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Eli Lilly and to earn $5.44 per share next year, which means the company should continue to be able to cover its $2.25 annual dividend with an expected future payout ratio of 41.4%.
Shares of LLY stock opened at $78.63 on Tuesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.41 and a quick ratio of 1.01. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09. The stock has a market cap of $85.10 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 1.36 and a beta of 0.26.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.21. Eli Lilly and had a return on equity of 35.37% and a net margin of 4.82%. The firm had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.51 billion. During the same quarter in the previous year, the company posted $0.98 earnings per share. The company’s revenue was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and will post 5.16 earnings per share for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 25th. The stock was sold at an average price of $80.85, for a total transaction of $14,553,000.00. Following the completion of the transaction, the insider now owns 122,896,904 shares of the company’s stock, valued at approximately $9,936,214,688.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey N. Simmons sold 9,027 shares of the company’s stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $78.50, for a total value of $708,619.50. The disclosure for this sale can be found here. Insiders have sold a total of 221,472 shares of company stock valued at $17,852,415 in the last ninety days. 0.11% of the stock is currently owned by corporate insiders.
LLY has been the subject of a number of recent research reports. Goldman Sachs lowered Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their target price for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Credit Suisse Group lowered Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price for the company. in a research note on Monday, January 22nd. Bank of America lowered their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Finally, BMO Capital Markets lowered their target price on Eli Lilly and from $79.00 to $78.00 and set a “market perform” rating for the company in a research note on Wednesday, April 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $93.11.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.